Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
Ibrutinib versus temsirolimus in patients with relapsed o... | ResearchHub
Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study
0
Authors
Martin Dreyling
27 more
Martin Dreyling
•
Fritz Offner
25 more
•
Simon Rule
Published
December 10, 2015
Paper
Conversation
0
Reviews
0
Bounties
0
Loading PDF viewer…
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
The Lancet
Topics
Biology
Materials Science
Medicine
Biochemistry
Cancer Oncology
Show all topics
DOI
10.1016/s0140-6736(15)00667-4
Other Formats
PDF
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
The Lancet
Topics
Biology
Materials Science
Medicine
Biochemistry
Cancer Oncology
Show all topics
DOI
10.1016/s0140-6736(15)00667-4
Other Formats
PDF
